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ORIGINAL ARTICLE
Time to disease-related pain and ﬁrst opioid use in patients with
metastatic castration-resistant prostate cancer treated with
sipuleucel-T
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1, CS Higano
2, PW Kantoff
3, JB Whitmore
4, MW Frohlich
4 and DP Petrylak
5
BACKGROUND: Sipuleucel-T has demonstrated improved overall survival in patients with metastatic castration-resistant prostate
cancer (mCRPC). This analysis examined the effect of sipuleucel-T on time to disease-related pain (TDRP) and time to ﬁrst use of
opioid analgesics (TFOA) in mCRPC using data pooled from three randomized phase III studies in men with asymptomatic or
minimally symptomatic mCRPC (D9901 (NCT00005947), D9902A (NCT01133704), D9902B (IMPACT; NCT00065442)).
METHODS: Four-hundred and twenty-eight asymptomatic patients were analyzed for TDRP; 737 patients were analyzed for TFOA.
Pain status was collected using logs adjudicated by blinded, independent reviewers. Opioid use for cancer-related pain was
identiﬁed from medically reviewed reports of concomitant medication. Disease-related pain was deﬁned as pain post enrollment.
TDRP and TFOA were analyzed using the Kaplan–Meier method and Cox regression.
RESULTS: Treatment with sipuleucel-T was not associated with a signiﬁcant difference in TDRP (hazard ratio (HR)¼0.819; 95%
conﬁdence interval (CI): 0.616–1.089; P¼0.170; median TDRP 5.6 months for sipuleucel-T and 5.3 months for control, respectively),
although 39.3% of sipuleucel-T-treated patients and 18.9% of control patients were pain-free at 12 months. However, there was a
signiﬁcant delay in TFOA with sipuleucel-T (HR¼0.755; 95% CI: 0.579–0.985; P¼0.038). Median TFOA for sipuleucel-T was 12.6, and
9.7 months for control, with 50.6% and 43.1% opioid-free at 12 months, respectively. Kaplan–Meier curves for both end points
began to diverge at 6 months.
CONCLUSIONS: Sipuleucel-T was associated with longer TFOA but not signiﬁcantly longer TDRP. Both end points demonstrated
evidence of a delayed treatment effect, consistent with an active immunotherapy.
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INTRODUCTION
The presence of pain in patients with metastatic castration-
resistant prostate cancer (mCRPC) is an adverse prognostic marker
for survival.
1,2 However, the delay in time to disease-related pain
(TDRP) or ﬁrst use of opioid analgesics (TFOA) provided by a
therapeutic agent, while clearly important clinical attributes, have
not been validated as prognostic or predictive markers. Data
regarding these attributes were prospectively collected in three
clinical trials evaluating sipuleucel-T (Provenge; Dendreon
Corporation, Seattle, WA, USA), and provided an opportunity to
explore these pain-related end points.
Sipuleucel-T is an autologous cellular immunotherapy designed
t os t i m u l a t ea ni m m u n er e s p o n s ea g a i n s tt h ep r o s t a t et u m o ra n t i g e n
prostatic acid phosphatase.
3,4 The efﬁcacy and safety of sipuleucel-T
in asymptomatic or minimally symptomatic mCRPC have been
investigated in three phase III trials. D9901 (NCT00005947)
demonstrated a signiﬁcant reduction in the risk of death with
sipuleucel-T versus control.
4 In D9902A (NCT01133704) a trend
towards improved survival was observed despite early discon-
tinuation of enrollment.
5 The pivotal IMPACT trial (D9902B
(NCT00065442)) demonstrated a signiﬁcant 22% reduction in the
risk of death (P¼0.03) with sipuleucel-T versus control and a
4.1-month improvement in median overall survival (OS).
6
In all three trials, TFOA and TDRP data were prospectively
collected in a blinded fashion and TDRP was a prospectively
deﬁned end point.
4–6 Given the similar study designs, a post hoc
pooled analysis was undertaken to increase the sample size and
improve the precision of treatment-effect estimates. TDRP was
analyzed for all patients known to be asymptomatic at enrollment.
TFOA was evaluated for all patients, irrespective of their symp-
tomatic status at enrollment.
MATERIALS AND METHODS
Study design
Table 1 summarizes the designs of the three phase III sipuleucel-T trials in
mCRPC.
4–6 All trials enrolled patients with Eastern Cooperative Oncology
Group performance status (ECOG PS) 0 or 1, average weekly pain score o4
(10-point visual analog scale) at registration, and no visceral metastases.
D9901/D9902A recruited only asymptomatic patients but with any Gleason
score (GS). IMPACT initially enrolled only asymptomatic patients with GS
p7, but was amended following data review from D9901 and D9902A to
include patients with any GS and minimally symptomatic disease (symptoms
not requiring treatment with opioid analgesics within 21 days before
registration). Pain correlating with a site of metastatic disease was allowed
provided it met the above pain score criterion. TDRP was a secondary end
point in D9901/D9902A, and data were intended to be pooled. Originally,
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end point; both end points were removed as the protocol amendment
allowed symptomatic patients and TDRP became irrelevant.
The intent-to-treat population for the TDRP analysis (n¼428) included
all randomized patients in D9901 (n¼127) and D9902A (n¼98), and
asymptomatic patients from IMPACT randomized prior to the protocol
amendment (n¼203). The intent-to-treat population for the TFOA analysis
(n¼737) included all randomized patients in D9901/D9902A/IMPACT.
Patients were randomized 2:1 to receive sipuleucel-T or control
4–6 and
were followed until disease progression (PD). After central conﬁrmation of
PD, patients were treated at the physician’s discretion. Control patients
could join an open-label salvage protocol and receive APC8015F, a product
manufactured similarly to sipuleucel-T but from the remaining cells
cryopreserved when the control was prepared.
Studies were conducted in compliance with US Food and Drug Admini-
stration and Good Clinical Practice guidelines, and met local Institutional
Review Board approvals. Written informed consent was obtained from all
patients.
Disease progression
For D9901/D9902A, the PD end point included progression of measurable
or evaluable disease (for example, lesions on bone scans), spinal-cord
compression or pathological fracture at known disease site(s), developing a
requirement for radiotherapy, or other clinically signiﬁcant disease-speciﬁc
events, including disease-related pain (DRP) or other symptoms.
4,5
For IMPACT, the PD end point included only objective PD, deﬁned as
ﬁrst progression of measurable or evaluable disease conﬁrmed by an inde-
pendent, blinded review committee.
6 No study used serum PSA increase to
measure PD.
TDRP and TFOA
In all studies, pain logs were collected and adjudicated by blinded,
independent reviewers. DRP was deﬁned as pain with a quality and
consistency of cancer-related pain that occurred after study enrollment
and anatomically correlated with the site(s) of radiographically demon-
strated disease. In D9901/D9902A, onset of DRP and opioid analgesic use
(OAU) were documented using a weekly log. Patients rated their pain from
0 (no pain) to 10 (pain as bad as can be imagined) for three questions from
the Brief Pain Inventory.
7 DRP was considered present if the patient had
unusual pain or a X3-point increase in intensity at a baseline pain site.
In IMPACT, pain and medication use were recorded with weekly
patient-completed logs and monthly investigator-completed logs. DRP
was considered present if pain was reported at a new site and the average
intensity was X2, and/or if existing pain intensity increased by X2 points
from screening. Date of pain onset was identiﬁed via a blinded, dual review
of pain logs and a ‘DRP’ worksheet that was completed when DRP was
identiﬁed.
In D9901/D9902A, pain and analgesic-use status was collected until DRP
occurred or for 4 weeks following PD, whichever happened ﬁrst. For
patients without DRP by 4 weeks after PD, data were censored at the last
available pain evaluation. In IMPACT, pain and medication status was
collected until DRP occurred, regardless of the time since PD. Following
protocol amendment, completion of pain logs was discontinued and data
were censored at the last pain evaluation for patients who had not reached
the pain end point.
A blinded medical review identiﬁed OAU by preferred drug names in the
coded concomitant medication information on case report forms, and
excluded OAU unrelated to cancer pain. OAU was excluded for procedures,
rigors related to infusions, lasting p2 days, or clearly unrelated to cancer.
TDRP and TFOA were deﬁned as the time from randomization to ﬁrst
identiﬁcation of DRP or OAU, respectively.
Statistical considerations
The individual studies were underpowered for the TDRP and TFOA end
points. Accordingly, statistical analysis was performed on pooled data. The
statistical analysis plan for D9901/D9902A prespeciﬁed that TDRP data
were to be pooled; these combined studies had 80% power to detect a
hazard ratio (HR) of 0.52 at the two-sided a¼0.05 level, provided that 80
pain events were observed. Prior to amendment, IMPACT had 90% power
to detect an HR of 0.562 at the two-sided a¼0.01 level, provided that 193
pain events were observed. Based on the 212 DRP events observed across
the three studies, a post hoc power analysis indicated there was 80%
power to detect an HR of 0.67 at the two-sided a¼0.05 level. Similarly,
based on 240 OAU events, a post hoc power analysis indicated there was
80% power to detect an HR of 0.68 at the two-sided a¼0.05 level.
TDRP and TFOA were summarized using the Kaplan–Meier method.
Two-tailed P-values, HRs and 95% conﬁdence intervals (CIs) were derived
from a Cox regression model, adjusted for baseline PSA and lactate
dehydrogenase (LDH) (both log-transformed). Integrated analyses were
stratiﬁed by study.
Post hoc exploratory analyses were conducted using two separate Cox
models, stratiﬁed by study and employing stepwise selection, to identify
independent predictors of TDRP or TFOA from the following: previous
chemotherapy, hemoglobin, PSA, alkaline phosphatase, LDH, age, number
of bone metastases, bisphosphonate use, GS, ECOG PS, weight, time
from diagnosis to randomization, previous primary radiotherapy, race
(Caucasian versus others), presence of soft tissue disease, and prior radical
prostatectomy. Treatment arm (sipuleucel-T or control) was included in the
resulting models to assess treatment effect after adjustment.
RESULTS
Patient characteristics and disposition
Figure 1 summarizes the disposition of patients included in the
TFOA and TDRP analyses. Patient characteristics were well
balanced between the arms (Table 2), although more sipuleucel-
T than control patients in the TDRP population had received
previous primary radiotherapy; there was no difference in prior
radiotherapy between the two arms for the TFOA analysis. Fewer
sipuleucel-T than control patients in both the TDRP and TFOA
populations had soft-tissue disease. A prognostic model incorpor-
ating baseline PSA, LDH, alkaline phosphatase, hemoglobin,
ECOG PS, GS and the presence of visceral disease
8 predicted
that survival for the sipuleucel-T and control arms, respectively,
was comparable for the TDRP (21.6 and 21.5 months) and TFOA
(20.1 and 20.1 months) populations. Of control patients, 99
(67.8%) in the TDRP population and 165 (66.3%) in the TFOA
population subsequently received APC8015F following PD.
Table 1. Study designs of D9901, D9902A, and IMPACT
Study design element or end
point
D9901 and D9902A IMPACT
(Sipuleucel-T, n¼147;
control, n¼78)
Pre-amendment (sipuleucel-T,
n¼135; control, n¼68)
Post-amendment (sipuleucel-T, n¼206;
control, n¼103)
Eligibility criteria Asymptomatic
All Gleason scores
Asymptomatic
Gleason score p7
Asymptomatic/minimally symptomatic
All Gleason scores
Overall survival Prespeciﬁed analysis Secondary end point Primary end point
Time to progression Primary end point Co-primary end point Secondary end point
Time to disease-related pain
(TDRP)
Secondary end point Co-primary end point End point removed; data collection
discontinued
Time to ﬁrst use of opioid
analgesics (TFOA)
Data collected Secondary end point End point removed; data collection
continued
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PD was documented in most of the 428 patients analyzed for
TDRP, with 243/282 (86.2%) sipuleucel-T and 132/146 (90.4%)
control patients progressing (Table 3a); DRP was documented
in 137/282 (48.6%) and 75/146 (51.4%) patients, respectively
(Table 3a). Censoring rates for TDRP were high in both the
sipuleucel-T (51.4%; 145/282) and control (48.6%; 71/146) arms
because pain logs were discontinued post-amendment in IMPACT
and determination of pain status was discontinued 4 weeks
following PD in D9901/D9902A, with PD occurring before pain in
57.3% (129/225) of these patients.
TDRP in the pooled analysis was not signiﬁcantly delayed with
sipuleucel-T versus control (HR¼0.819; 95% CI: 0.616–1.089;
P¼0.170) (Table 4a). Median estimated TDRP was 5.6 months
(95% CI: 4.3–7.8) with sipuleucel-T versus 5.3 months (95% CI: 3.7–
7.7) with control. However, the Kaplan–Meier curves of TDRP
begin to diverge B6 months following randomization (Figure 2).
At 12 months, 39.3% of sipuleucel-T and 18.9% of control patients
were estimated as pain-free. There was directional consistency
between D9901 and IMPACT, but not D9902A (Table 4a). However,
the sample size was smaller in D9902A as enrollment was
discontinued early and several baseline factors favored the control
arm, including PSA, alkaline phosphatase, LDH and the number of
bone metastases.
5
A stepwise Cox regression model identiﬁed the following factors
as prognostic for earlier TDRP: higher PSA (HR¼1.264; 95% CI:
1.133–1.409; Po0.001); higher alkaline phosphatase (HR¼1.486;
95% CI: 1.208–1.828; Po0.001); younger age (per year decrease)
(HR¼1.024; 95% CI: 1.007–1.041; P¼0.005); bisphosphonate use
(HR¼1.600; 95% CI: 1.171–2.188; P¼0.003); and prior primary
radiotherapy (HR¼1.596; 95% CI: 1.199–2.126; P¼0.001). When
adjusting for these factors, results were comparable (HR¼0.804;
95% CI: 0.602–1.076; P¼0.142) (Table 4a).
In IMPACT, where TDRP was recorded regardless of PD status,
longer TDRP was associated with longer time to PD and OS (both
Po0.001). Median TDRP in IMPACT was 4 months. In patients with
TDRP p4 versus 44 months, respectively, median time to PD was
10.3 versus 34.7 weeks, and median OS was 22.3 versus 37.0
months.
TFOA
Table 3b provides a summary of OAU and PD status for all patients
(n¼737). OAU for reasons other than cancer-associated pain (for
example, meperidine use for rigors on infusion day) was excluded
and is summarized in Table 5. Most patients experienced PD, with
419/488 (85.9%) sipuleucel-T and 216/249 (86.7%) control patients
progressing; OAU occurred in 153/488 (31.4%) and 87/249 (34.9%)
patients, respectively.
TFOA was signiﬁcantly delayed for sipuleucel-T versus control
(HR¼0.755; 95% CI: 0.579–0.985; P¼0.038) (Table 4b). Median
TFOA was 12.6 months (95% CI: 9.3—not estimable) with
sipuleucel-T versus 9.7 months (95% CI: 6.0—not estimable)
with control. The censoring rate was high (335/488 (68.6%) and
162/249 (65.1%) patients, respectively). Kaplan–Meier estimates
of being opioid-free at 12 months were 50.6% for sipuleucel-T
compared with 43.1% for control, and curve separation began at
6 months (Figure 3). TFOA results for D9901 and IMPACT, but not
D9902A, showed directional consistency (Table 4b) similar to the
TDRP analysis.
5
Signiﬁcant baseline predictors of shorter TFOA were: higher
PSA, alkaline phosphatase and LDH; younger age; higher number
of bone metastases; GS X8; ECOG PS 1; higher weight; and prior
primary radiotherapy. HR adjusted for these predictors of TFOA
was 0.754 (95% CI: 0.571–0.995; P¼0.046) (Table 4b).
DISCUSSION
Approximately 90% of patients who die of prostate cancer have
bone metastases,
9 and many experience associated bone pain and
Assessed for eligibility (n = 1294)
D9901 (n = 186)
D9902A (n = 182)
IMPACT (n = 926)
Randomized (n = 737)
D9901 (n = 127)
D9902A (n = 98)
IMPACT (n = 512)
￿ Underwent leukapheresis (n = 485)
￿ Received sipuleucel-T (n = 476)
￿ Did not receive sipuleucel-T (n = 9)
￿ Underwent leukapheresis (n = 246)
￿ Received control (n = 243)
￿ Did not receive control (n = 3)
￿ Reported opioid use
  (n = 153)
￿ Censored (n = 335)
Analyzed for TFOA (n = 488) Analyzed for TDRP (n = 282)
￿ Reported disease-related
  pain (n = 137)
￿ Censored (n = 145)
Analyzed for TFOA (n = 249)
￿ Reported opioid use (n = 87)
￿ Censored (n = 162)
Analyzed for TDRP (n = 146)
￿ Reported disease-related
   pain (n = 75)
￿ Censored (n = 71)
Assigned to receive sipuleucel-T (n = 488) Assigned to receive control (n = 249)
Excluded (n = 557)
￿ Not meeting inclusion criteria (n = 448)
￿ Declined to participate (n = 46)
￿ Other reasons (n = 63)
Figure 1. Patient enrollment and outcomes. TDRP, time to disease-related pain; TFOA, time to ﬁrst use of opioid analgesics.
Delay in pain and opioids: sipuleucel-T
EJ Small et al
261
& 2014 Macmillan Publishers Limited Prostate Cancer and Prostatic Disease (2014), 259–264receive opioid analgesics.
10 In addition to its obvious impact on
quality of life, pain is an important prognostic factor in mCRPC.
A retrospective study of 599 mCRPC patients showed a statistically
signiﬁcant impact of pain on survival time.
1 Similarly, clinically
signiﬁcant pain was one of the most important independent
prognostic factors for OS (HR¼1.48; Po0.0001) in the pivotal
docetaxel TAX327 study of 1006 mCRPC patients.
2
This analysis of pooled data from three randomized trials
demonstrated a signiﬁcant difference in TFOA for patients treated
with sipuleucel-T versus control, but no signiﬁcant difference in
TDRP. Immunotherapies may show a delayed antitumor effect,
11
which is supported by the divergence of the TFOA and TDRP
Kaplan–Meier curves after 6 months and the approximately
two-fold increase in patients remaining DRP free at 12 months
with sipuleucel-T versus control. Objective PD tended to predate
DRP, which in turn preceded OAU (for sipuleucel-T and control,
Table 2. Summary of patient demographics and baseline characteristics
Baseline patient demographic or characteristic TDRP analysis population TFOA analysis population
Sipuleucel-T
(n¼282)
Control
(n¼146)
Total
(n¼428)
Sipuleucel-T
(n¼488)
Control
(n¼249)
Total
(n¼737)
Median age, years (minimum, maximum) 72 (47, 89) 70 (45, 87) 71 (45, 89) 72 (47, 91) 71 (40, 89) 71 (40, 91)
Median weight, kg (minimum, maximum) 88 (55, 159) 86 (60, 136) 87 (55, 159) 88 (53, 175) 86 (60, 136) 87 (53, 175)
Caucasian, n (%) 261 (92.6) 136 (93.2) 397 (92.8) 437 (89.5) 229 (92.0) 666 (90.4)
ECOG PS 0, n (%) 236 (83.7) 117 (80.1) 353 (82.5) 393 (80.5) 199 (79.9) 592 (80.3)
Gleason score, n (%)
p6 53 (18.8) 23 (15.8) 76 (17.8) 74 (15.2) 31 (12.4) 105 (14.2)
7 176 (62.4) 87 (59.6) 263 (61.4) 277 (56.8) 140 (56.2) 417 (56.6)
X8 52 (18.4) 36 (24.7) 88 (20.6) 136 (27.9) 77 (30.9) 213 (28.9)
Missing 1 (0.4) 0 1 (0.2) 1 (0.2) 1 (0.4) 2 (0.3)
Number of bone metastases, n (%)
0–5 125 (44.3) 72 (49.3) 197 (46.0) 206 (42.2) 112 (45.0) 318 (43.1)
6–10 40 (14.2) 26 (17.8) 66 (15.4) 67 (13.7) 39 (15.7) 106 (14.4)
410 113 (40.1) 47 (32.2) 160 (37.4) 211 (43.2) 97 (39.0) 308 (41.8)
Missing 4 (1.4) 1 (0.7) 5 (1.2) 4 (0.8) 1 (0.4) 5 (0.7)
Soft-tissue disease, n (%) 150 (53.6)
a 92 (64.3)
a 242 (57.2) 248 (51.0)
a 152 (61.8)
a 400 (54.6)
Median serum PSA, ngml
 1b 44.7 44.5 44.7 51.5 46.6 49.9
Median alkaline phosphatase, Ul
 1c 99.0 103.0 100.0 103.0 104.0 103.0
Median LDH, Ul
 1d 186.5 184.5 186.0 190.0 187.5 190.0
Median hemoglobin, gdl
 1e 13.0 13.1 13.1 12.9 12.7 12.9
Treatment history, n (%)
Combined androgen blockade 245 (86.9) 129 (88.4) 374 (87.4) 411 (84.2) 213 (85.5) 624 (84.7)
Orchiectomy 47 (16.7) 24 (16.4) 71 (16.6) 66 (13.5) 28 (11.2) 94 (12.8)
Chemotherapy 28 (9.9) 14 (9.6) 42 (9.8) 77 (15.8) 33 (13.3) 110 (14.9)
Docetaxel 13 (4.6) 7 (4.8) 20 (4.7) 55 (11.3) 22 (8.8) 77 (10.4)
Radical prostatectomy 107 (37.9) 47 (32.2) 154 (36.0) 180 (36.9) 82 (32.9) 262 (35.5)
Radiotherapy (to the prostate/prostate bed) 163 (57.8)
a 69 (47.3)
a 232 (54.2) 267 (54.7) 127 (51.0) 394 (53.5)
Median time from diagnosis to randomization, years 6.8 7.1 7.0 6.8 6.8 6.8
Current bisphosphonate use, n (%) 70 (24.8) 36 (24.7) 106 (24.8) 175 (35.9) 88 (35.3) 263 (35.7)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; TDRP, time to disease-related pain; TFOA, time
to ﬁrst use of opioid analgesics.
aPo0.05 for comparison of sipuleucel-T and control. Fisher’s exact test for categorical variables and Wilcoxon rank-sum test for continuous variables.
bNormal range p2.7–7.2ngml
 1.
cNormal range 31–131Ul
 1.
dNormal range 53–234Ul
 1.
eNormal range 12.5–18.1gdl
 1.
Table 3a. Summary of disease progression and pain status in time to
disease-related pain (TDRP) population
Patient disposition Sipuleucel-T, n (%)
(n¼282)
Control, n (%)
(n¼146)
Pain and disease progression 125 (44.3) 69 (47.3)
Disease progression only 118 (41.8) 63 (43.2)
Pain only 12 (4.3) 6 (4.1)
No pain or disease progression 27 (9.6) 8 (5.5)
Table 3b. Summary of disease progression and opioid use in time to
ﬁrst use of opioid analgesics (TFOA) population
Patient disposition Sipuleucel-T, n (%)
(n¼488)
Control, n (%)
(n¼249)
Opioid use and disease
progression
139 (28.5) 76 (30.5)
Disease progression only 280 (57.4) 140 (56.2)
Opioid use only 14 (2.9) 11 (4.4)
No opioid use or disease
progression
55 (11.3) 22 (8.8)
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months;
6 in this pooled analysis, median TDRP was 5.6 and 5.3
months, and median TFOA was 12.6 and 9.7 months). Given the
suggested delayed effect of immunotherapy, the relative kinetics
of these end points may explain the increasingly greater
treatment effects observed on PD, TDRP and TFOA, successively.
In stepwise logistic regression analyses, several baseline factors
were prognostic for earlier TDRP or TFOA. The association of
higher PSA, alkaline phosphatase, LDH, number of bone meta-
stases and ECOG PS with shorter TDRP and/or TFOA is consistent
with these being baseline markers of more advanced disease.
Although the shorter TDRP in patients receiving bisphosphonates
seems counterintuitive, bisphosphonate treatment is more
common in patients with a higher disease burden. Androgen
deprivation therapy treatment is associated with a high risk of
clinical fractures so current NCCN guidelines recommend that
patients receiving androgen deprivation therapy should also
receive bisphosphonates (denosumab, zoledronic acid, or alen-
dronate) when there is an absolute fracture risk.
12 Higher GS as an
indicator for earlier TFOA is consistent with GS being a marker for
more aggressive disease.
2,8 There is no immediate explanation for
the association of younger age or primary radiotherapy with
shorter TDRP or TFOA. Importantly, the trend towards delayed
TDRP and signiﬁcantly delayed TFOA with sipuleucel-T versus
control were maintained after adjusting for these factors, suggest-
ing that any differences in baseline prognostic factors would not
explain the TDRP or TFOA ﬁndings.
The delayed antitumor effect of sipuleucel-T may account for
the greater treatment effect on later events, such as OAU (TFOA),
relative to earlier events, such as DRP (TDRP), or even earlier
events such as PD (time to PD). However, the lack of statistical
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Figure 2. Kaplan–Meier analysis of time to disease-related pain in
the pooled data set (intent-to-treat population).
Table 5. Opioid use excluded from analysis
Reason for excluding
opioid use
a
Sipuleucel-T, n
(%) (n¼488)
Control, n
(%) (n¼249)
Total, n
(%) (n¼737)
Any excluded opioid 163 (33.4) 34 (13.7) 197 (26.7)
Rigors due to infusion
b 116 (23.8) 6 (2.4) 122 (16.6)
Procedure
c 26 (5.3) 16 (6.4) 42 (5.7)
Short duration
d 38 (7.8) 12 (4.8) 50 (6.8)
Other
e 9 (1.8) 4 (1.6) 13 (1.8)
aPatients with multiple excluded opioids are counted once for each
reported category.
bTypically rigors and/or chills on the day of an infusion, treated with 1 day
of meperidine.
cFor example, anesthesia or procedure-related pain.
dOpioids given for 1 or 2 days for reasons other than above (e.g., pain,
shortness of breath, respiratory distress).
eOpioids given for 42 days for reasons clearly not due to cancer-related
pain (e.g., cough, infection, pain due to injury or accident).
Table 4b. Association between sipuleucel-T treatment and time to
ﬁrst use of opioid analgesics
Study Hazard
ratio
95% conﬁdence
interval
P-value
D9901 0.629 0.304–1.303 0.212
D9902A 1.242 0.544–2.833 0.607
IMPACT 0.727 0.536–0.987 0.041
Integrated result 0.755 0.579–0.985 0.038
Adjusted integrated result
a 0.754 0.571–0.995 0.046
aAdjusted for the signiﬁcant baseline predictors of shorter time to disease-
related pain (higher PSA, higher alkaline phosphatase, higher lactate
dehydrogenase, younger age, higher number of bone metastases, Gleason
score X8, Eastern Cooperative Oncology Group performance status 1,
higher weight, prior radiotherapy).
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Figure 3. Kaplan–Meier analysis of time to ﬁrst use of opioid
analgesics.
Table 4a. Association between sipuleucel-T treatment and time to
disease-related pain (TDRP)
Study Hazard
ratio
95% conﬁdence
interval
P-value
D9901 0.681 0.373–1.246 0.210
D9902A 1.392 0.652–2.973 0.390
IMPACT 0.802 0.560–1.149 0.227
Integrated result 0.819 0.616–1.089 0.170
Adjusted integrated result
a 0.804 0.602–1.076 0.142
aAdjusted for the signiﬁcant baseline predictors of shorter TDRP (higher
PSA, higher alkaline phosphatase, younger age, bisphosphonate use and
prior primary radiotherapy).
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amount of censoring (50.5% of patients) and the relatively small
sample size (212 observed pain events; 4700 pain events would
be required to provide 80% power (a¼0.05) to detect a true HR
of 0.80).
Two randomized phase III studies (NCT01057810 and
NCT00861614) are currently evaluating ipilimumab versus placebo
for CRPC using pain-related secondary end points. Furthermore,
conﬁrmed pain response is the primary outcome (data anticipated
in Q3 2014) in the randomized COMET-2 phase III study
(NCT01522443) that is evaluating cabozantinib versus mitoxan-
trone plus prednisone in men with previously treated sympto-
matic CRPC.
This analysis has several limitations, most notably its post hoc
nature. For example, while the medical review that was used to
exclude OAU unrelated to cancer pain was blinded, the criteria
were identiﬁed post hoc and may have led to differential exclusion
favoring one arm over the other. Other limitations are the high
degree of censoring and the fact that, individually, each study was
not adequately powered for TDRP or TFOA analysis, requiring data
pooling.
Nevertheless, this analysis has demonstrated a signiﬁcant delay
in TFOA across the pooled population, irrespective of baseline
symptomatic status. The TFOA ﬁndings and trend in TDRP are
consistent with the delayed antitumor effect reported with
immunotherapy in this patient population, and suggest that
further study of clinical end points proximate to OS (such as TDRP
and TFOA) is warranted.
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